4DMedical Names Long-Serving Director Julian Sutton as CFO to Drive Global Scale-Up

An update from 4DMedical Ltd ( (AU:4DX) ) is now available.

4DMedical has strengthened its leadership team by appointing long-serving non-executive director and early investor Julian Sutton as Chief Financial Officer and Executive Director, formalising his strategic role after years of involvement in capital strategy, corporate governance and funding activities. The move comes as the company reports strong commercial momentum, with its CT:VQ imaging solution now FDA-cleared and in use at leading U.S. academic medical centres, alongside a global distribution agreement with Philips, positioning 4DMedical for accelerated global scale-up and signalling a focus on executing its commercial strategy and long-term value creation for shareholders.

The most recent analyst rating on (AU:4DX) stock is a Hold with a A$3.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

More about 4DMedical Ltd

4DMedical Limited is a global medical technology company specialising in advanced respiratory imaging and artificial intelligence. Its patented XV Technology transforms standard medical scans into detailed functional insights to help physicians detect, diagnose and monitor lung disease earlier and more precisely. The company’s software portfolio includes FDA-cleared XV Lung Ventilation Analysis Software, CT LVAS and CT:VQ, a cardiothoracic imaging solution that combines ventilation and perfusion analysis, all delivered via a SaaS model that integrates into existing hospital systems to enhance clinician productivity and enable more personalised care. Following its 2023 acquisition of Imbio, 4DMedical has expanded its AI capabilities and is focused on redefining respiratory disease management worldwide.

Average Trading Volume: 4,756,835

Technical Sentiment Signal: Buy

Current Market Cap: A$2.13B

Learn more about 4DX stock on TipRanks’ Stock Analysis page.